Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2019-11-12 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Antisense Therapeutics Listed Option ANPOB Exercise 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 13 November 2019 regarding the exercise of listed options (ASX:ANPOB) by option holders. It discusses the sending of option exercise forms and instructions for converting options into fully paid ordinary shares. There is no financial data, no report attached or referenced, and the document is short (921 characters). It is an announcement about a capital-related event (option exercise leading to share conversion), which fits best under Capital/Financing Update (CAP).
2019-11-12 English
Appendix 3B 13 pages 263.6KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, issue price, purpose, and compliance with ASX rules. It also includes calculations related to placement capacity under ASX Listing Rules 7.1 and 7.1A, which govern the issuance of new shares and capital raising activities. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new share issue and application for quotation of additional securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2019-11-11 English
Notice of Annual General Meeting/Proxy Form 92 pages 10.2MB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes details about the AGM date, location, and agenda items such as the 2019 Annual Financial Report, resolutions for adoption of the Remuneration Report, re-election of directors, ratification of share issues, approval of option issues to directors, and approval of an Employee Share Option Plan. It also includes proxy forms and explanatory notes. The document is a notice sent to shareholders to inform them about the upcoming AGM and the matters to be voted on. It does not contain the actual Annual Report or financial statements but references them as part of the meeting agenda. The document length is about 15,000 characters, which is consistent with a detailed AGM notice including explanatory notes and proxy forms. Therefore, this document is best classified as AGM Information (AGM-R).
2019-11-10 English
Annual Report 64 pages 8.9MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2019' and contains detailed sections typical of an annual report, including Operations Report, Intellectual Property Report, Directors' Report, Auditor Independence Declaration, Corporate Governance, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, Independent Auditor's Report, and Shareholder Information. The length is substantial (15,000 characters), indicating a full report rather than a brief announcement. The content includes comprehensive descriptions of company activities, clinical trials, partnerships, financial and operational updates, and events after the balance sheet date, all consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2019
2019-10-30 English
Appendix 4G 13 pages 212.4KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures that must accompany the annual report. It includes a detailed key to disclosures against the Corporate Governance Council Principles and Recommendations for the financial year ended 30 June 2019. The document states that the corporate governance statement is part of the annual report (pages 21 to 26) and also available on the company's website. The content is focused on governance practices, board roles, committee charters, diversity policies, and compliance with governance recommendations. It is not the full annual report itself but a regulatory filing that accompanies the annual report to comply with ASX listing rules. The document is not a report publication announcement since it contains substantive governance disclosure information rather than just announcing the report's availability. Therefore, the document fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2019-10-30 English
Appendix 3B 13 pages 263.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, issue price, purpose, and compliance with ASX rules. It also includes calculations related to placement capacity under ASX Listing Rules 7.1 and 7.1A, which govern the issuance of new shares and placement capacity for eligible entities. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding the issue of additional shares and related securities. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and share issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is a substantive announcement, not merely a report publication announcement or a regulatory filing fallback.
2019-10-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.